GC Green Cross Sells U.S. Affiliate Curevo to Eli Lilly
Lilly Acquires All Issued Shares of Curevo
GC Green Cross announced that its U.S. affiliate, Curevo Vaccine (Curevo), has signed an agreement to transfer all of its issued shares to global pharmaceutical company Eli Lilly. Under the agreement, Lilly will acquire 100% ownership of Curevo and secure the rights to 'amezosvatein' (project name CRV-101), Curevo's next-generation shingles vaccine candidate currently under development.
Exterior view of the GC Green Cross headquarters in Giheung District, Yongin-si, Gyeonggi-do. GC Green Cross
View original imageThe total value of the deal is up to 1.5 billion dollars (approximately 2.2612 trillion won). Upon the closing of the transaction, an upfront payment will be made, and additional potential milestone payments will be received if certain conditions are met during the future commercialization process. GC Green Cross, which holds a 20.3% stake in Curevo, will receive a proportionate share of the upfront payment upon closing, and this will be reflected in its future net profit.
This agreement reflects the clinical value of amezosvatein. Amezosvatein has demonstrated non-inferior immunogenicity and superior tolerability in a head-to-head global Phase II clinical trial against GSK's shingles vaccine, Shingrix.
GC Green Cross has established a diversified mid- to long-term revenue structure, which includes proceeds from the sale of its Curevo stake, potential milestone payments, potential contract manufacturing (CMO) revenue, and potential sales-based royalties.
Euncheol Heo, CEO of GC Green Cross, stated, "This transaction is a recognition of the value of our R&D investment and collaborative strategy that has been ongoing since the early days of Curevo's establishment. It is significant not only as a recovery of our investment but also as a means to secure a stable cash flow structure through potential future business opportunities." He added, "We will continue to expand differentiated asset development and strategic investments targeting the global market."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Meanwhile, GC Green Cross plans to use the proceeds from this sale for the development of subcutaneous immunoglobulin (SCIG), premium vaccines, and innovative orphan drugs.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.